Van Agthoven M, Heule-Dieleman HAG, De Boer MF, Kaanders JHAM, Baatenburg de Jong RJ, Kremer B, Leemans CR, Marres HAM, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, De Jong JMA, Uyl-de Groot CA, Knegt PP. Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas. Radiother Oncol 2005; 74: 337-344.

Van Agthoven M, Kramer MHH, Sonneveld P, van der Hem KG, Huijgens PC, Wijermans PW, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A. Cost analysis of common treatment options for indolent follicular non-Hodgkin’s lymphoma. Haematologica 2005; 90: 1422-1432.

Van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA. Cost determinants in aggressive non-Hodgkin’s lymphoma. Haematologica 2005; 90: 661-671.

Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. J Hypertens 2005; 23 :913-20.

Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Press Monit 2005; 10: 243-8.

Agyemang C, Redekop WK, Owusu-Dabo E, Bruijnzeels MA. Blood pressure patterns in rural, semi-urban and urban children in the Ashanti region of Ghana, West Africa. BMC Public Health 2005; 5: 114.

Al MJ, Feenstra TL, van Hout BA. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Econ 2005; 14: 655-667.

Baltussen R, Brouwer W, Niessen L. Cost-effectiveness analysis for priority setting in health: penny-wise but pound-foolish. Int J Technol Assess Health Care 2005; 21: 532-4.

Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. Br Med J 2005; 331: 1364-1370.

Baltussen RM, Sylla M, Frick KD, Mariotti SP. Cost-effectiveness of trachoma control in seven world regions.Ophthalmic Epidemiol 2005; 12: 91-101.

Beersen N, Redekop WK, de Bruijn JH, Theuvenet PJ, Berg M, Klazinga NS. Quality based social insurance coverage and payment of the application of a high cost medical therapy: the case of spinal cord stimulation for chronic non-oncologic pain in The Netherlands. Health Policy 2005; 71: 107-15.

Bekkering GE, Van Tulder MW, Hendriks EJM, Koopmanschap MA, Knol DL, Bouter LM, Oostendorp RAB. Implementation of clinical guidelines on physical therapy for patients with low back pain: randomized trial comparing patient outcomes after a standard and active implementation strategy. Phys Ther 2005; 85: 544-55.

Van den Berg B, Al MJ, Brouwer WBF, Van Exel NJA, Koopmanschap MA. Economic valuation of informal care: the conjoint measurement method applied to informal caregiving. Soc Sci Med 2005; 61: 1342-1355.

Van den Berg B, Bleichrodt H, Eeckhoudt L. The economic value of informal care: a study of informal caregivers’ and patients’ willingness to pay and willingness to accept for informal care. Health Economics 2005; 14: 363-376.

Van den Berg B, Brouwer WBF, Van Exel NJA, Koopmanschap MA. Economic valuation of informal care: the contingent valuation method applied to informal caregiving. Health Economics 2005; 14: 169-183.

Bleichrodt H, Doctor J, Stolk EA. A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis. J Health Econ 2005; 24: 655-678.

Braaksma M, Van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostine.European Journal of Cancer 2005; 41: 2102-2111.

De Bree R, Hoekstra OS, Van der Putten L, Boers M, Uyl-de Groot CA, Leemans CR. Recidief larynxcarcinoom na radiotherapie-PET-studie: RELAPS. Nederlands Tijdschrift voor Oncologie 2005; 2: 117-119.

Brouwer WBF. Ongelijkheid om positief te prikkelen: nuttig en rechtvaardig. TSG 2005; 83: 181-182.

Brouwer WBF, Van Exel NJA. Expectations about length and health related quality of life. Soc Sci Med 2005; 61: 1083-1094.

Brouwer WBF, Van Exel NJA, Van den Berg B, Van den Bos GAM, Koopmanschap MA. Process utility from providing informal care: The benefit of caring. Health Policy 2005; 74: 85-99.

Brouwer WBF, Van Exel NJA, Stolk EA. Acceptability of less than perfect health states. Soc Sci Med 2005; 60: 237-246.

Brouwer WBF, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free?Pharmacoeconomics 2005; 23: 105-111.

Brouwer WBF, Meerding WJ, Lamers LM, Severens JL. The Relationship between Productivity and Health-Related QOL: An Exploration. Pharmacoeconomics 2005; 23: 209-18.

Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331: 446-448.

Brouwer WBF, Rutten FFH. Optimale zorg dient onafhankelijk te worden vastgesteld, juist nu! TSG 2005; 83: 326-329.

Cohen JP. Emergence of a fourth hurdle. Regulatory Affairs Journal 2005; 16: 495-499.

Cohen JP, Paquette C, Cairnes C. Switching prescription drugs over-the-counter. Br Med J 2005; 330: 39-42.

Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.

Doorduijn J, Buijt I, Van der Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005; 75: 116-123.

Van Exel NJ, Koopmanschap MA, Scholte Op Reimer W, Niessen LW, Huijsman R. Cost-effectiveness of integrated stroke services. QJM 2005; 98: 415-25.

Van Exel NJA, Koopmanschap MA, Van den Berg B, Brouwer WBF, Van den Bos GAM. Burden of informal caregiving for stroke patients. Identification of Caregivers at risk of adverse health effects. Cerebrovasc Dis 2005; 19: 11-17.

Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178-90.

Goor KM, Schaafsma MR, Huijgens PC, Van Agthoven M. Economic assessment on the management of chronic lymphocytic leukaemia. Expert Opin Pharmacother 2005; 6: 1179-1189.

Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol 2005; 74: 194-202.

Hart HE, Redekop WK, Berg M, Bilo HJ, Meyboom-de Jong B. Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. J Clin Epidemiol 2005; 58: 1158-64.

Hart HE, Redekop WK, Bilo HJ, Berg M, Jong BM. Change in perceived health and functioning over time in patients with type I diabetes mellitus. Qual Life Res 2005; 14: 1-10.

Hoeijenbos M, Bekkering T, Lamers L, Hendriks E, van Tulder M, Koopmanschap M. Cost-effectiveness of an active implementation strategy for the Dutch physiotherapy guideline for low back pain. Health Policy 2005; 75: 85-98.

Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Br Med J 2005; 331: 1431-1437.

Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26: 223-233.

Hutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan 2005; 20: 252-259.

Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 200; 14: 435-43.

Klok RM, Brouwer WBF, Annemans LA, Bos JM, Postma MJ. Towards a healthier discount procedure. Exp Rev Pharmacoeconomics Outcomes Res 2005; 5: 59-63.

Koopmans GT, Donker MCH, Rutten FFH. Common mental disorders and use of general health services: a review of the literature on population-based studies. Acta Psychiatr Scand 2005; 111: 341-50.

Koopmans GT, Donker MCH, Rutten FFH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005; 27: 44-56.

Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 23-28.

Koopmanschap MA, Brouwer WBF, Hakkaart-van Roijen L, Van Exel NJA. The influence of waiting time on cost-effectiveness. Soc Sci Med 2005; 60: 2501-2504.

Koopmanschap MA, Burdorf A, Jacob K, Meerding WJ, Brouwer WBF, Severens JL. Productivity and health in economic evaluation; setting the research agenda. PharmacoEconomics 2005; 23: 47-54.

Lamers LM, Meerding WJ, Severens H, Brouwer WBF. The relationship between productivity and health related quality of life: an empirical exploration in persons with low back pain. Quality of Life Research 2005; 14: 805-813.

Lamers LM, Stalmeier PFM, McDonnell J, Krabbe PFM, Van Busschbach JJ. Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief. Ned Tijdschr Geneeskd 2005; 149: 1574-8.

Lee KS, Brouwer WBF, Lee SI, Koo HW. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations.Pharmacoeconomics 2005; 23: 709-721.

Liedgens H, Nuijten MJC, Poulsen Nautrup B. Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in The Netherlands. J Appl Ther Res 2005; 25: 785-802.

Lombarts MJMH, Klazinga NS, Redekop K. Measuring the perceived impact of implementing recommendations from external assessment: lessons from the Dutch visitatie programme for medical specialists. J Eval Clin Pract 2005; 11: 587-597.

Meerding WJ, IJzelenberg W, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol 2005; 58: 517-23.

Nijdam W, Levendag P, Noever I, Uyl-de Groot C, van Agthoven M. Cancer in the oropharynx: Cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications.Radiother Oncol 2005; 77: 65-72.

Nuijten MJC. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23: 851-853.

Nuijten MJC, Poulsen Nautrup B. Economic evaluation of a tramadol/paracetamol combination vs. tramadol in subacute low back pain in The Netherlands. J Appl Ther Res 2005; 5: 17-28.

Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-776.

Oostenbrink JB, Kok ET, Verheul RM. A comparative study of resource use and costs of renal, liver and heart transplantation. Transpl Int 2005; 18: 437-43.

Oostenbrink JB, Rutten-van Mölken MPMH, Monz BU, Fitzgerald JM. Probabilistic Markov model to assess the cost-effectiveness of broncholidator therapy in COPD patients in different countries. Value Health 2005; 18: 32-46.

Oppe M, Weijnen ThJG, de Charro, FTh. Development of a questionnaire to assess the quality of care in Dutch dialysis centers from the patient’s perspective. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 255-265.

Polinder S, Meerding WJ, Van Exel NJA, Brouwer WBF. Societal discounting of health effects in cost-effectiveness analyses : the influence of life expectancy. Pharmacoeconomics 2005; 23: 791-802.

De Raad J, Redekop WK. Analysis of health factors as predictors for the functioning of military personnel: study of the factors that predict fitness for duty and medical costs of soldiers of the Royal Netherlands Army. Mil Med 2005; 170: 14-20.

Rutten FFH, Brouwer WBF, Niessen LW. Practice guidelines based on clinical and economic evidence: indispensable tools in future market-oriented health care. Eur J Health Econ 2005; 6: 91-93.

Sendi P, Brouwer WBF. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ 2005; 14: 643-647.

Sittl R, Nuijten MJC, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005; 27: 1022-1031.

Stalmeier PF, Busschbach JJ, Lamers LM, Krabbe PF. The gap effect: discontinuities of preferences around dead. Health Econ. 2005; 14: 679-85.

Steinbusch P, Van Exel NJA, Huijsman R. Ketenzorg voor CVA-patiënten. Medisch Contact 2005; 60: 200-201.

Stolk EA, Pickee SJ, Ament AHJA, Busschbach JJV. Equity in health care prioritization: an empirical inquiry into social value. Health Policy 2005; 74: 343-55.

Stolk EA, Poley MJ. Criteria for determining a basic health service package. Recent developments in The Netherlands. Eur J Health Econ 2005; 6: 2-7.

Stolk EA, Rutten FFH. The Health Benefit Basket in The Netherlands. Eur J Health Econ 2005; 6 Suppl 1: 53-57.

Uyl-de Groot CA, Buijt I, Gloudemans IJM, Ossenkoppele GJ, Van den Berg HP, Huijgens PC. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005; 74: 136-143.

Uyl-de Groot CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005; 17: 392-396.

Uyl-de Groot CA, McDonnell J, Groen HJM, Radice D, Ten Velde G. Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small cell lung cancer: Results of a Markov chain model. Eur J Hosp Pharm Sci 2005; 2: 37-41.

Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005; 23: 2379-87.

De Wolf P, Brouwer WBF, Rutten FFH. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20: 351-374.